Clinical Accuracy of a New Rapid Assay for Fecal Calprotectin Measurement

Ashorov, Olga; Hamouda, Dalal; Dickman, Ram; Perets, Tsachi Tsadok

doi:10.7754/clin.lab.2020.200126

Cited by 6 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, CRP has been noted to have different responses in IBDs with higher concentration being noted in CD patients when compared with UC. 52 Fecal calprotectin is more sensitive than serum markers for detection of gut inflammation, 53 but increased levels have also been noted in gastrointestinal infections, neoplasia, and polyps, 54 further reaffirming the need to explore novel markers of disease activity in IBDs. The data presented in the current study demonstrate elevated serum levels of 5-HT in active CD and provide evidence that 5-HT can discriminate between disease activity states in CD better than CRP.…”

Section: Discussionmentioning

confidence: 99%

Serum Serotonin Differentiates Between Disease Activity States in Crohn’s Patients

Manzella

Jayawardena

Pagani

et al. 2020

Inflammatory Bowel Diseases

View full text Add to dashboard Cite

Background Diagnosis and monitoring of inflammatory bowel diseases (IBDs) utilize invasive methods including endoscopy and tissue biopsy, with blood tests being less specific for IBDs. Substantial evidence has implicated involvement of the neurohormone serotonin (5-hydroxytryptamine, 5-HT) in the pathophysiology of IBDs. The current study investigated whether serum 5-HT is elevated in patients with active ulcerative colitis (UC) or Crohn’s disease (CD). Methods Serum samples were obtained from a German cohort of 96 CD and UC patients with active disease, refractory disease, or remission of disease based upon their disease activity index (DAI) and disease history. High pressure liquid chromatography with tandemmass spectrometry was used to measure 5-HT, tryptophan (TRP), and kynurenine (KYN) levels in the serum samples, and Luminex Multiplex ELISA was used to measure cytokine levels. Intestinal mucosal biopsies were obtained from a separate cohort of healthy and CD patients, and the immunoreactivity of the serotonin transporter (SERT) was determined. Results There was no statistically significant difference in TRP or KYN levels between disease categories in either UC or CD. Interestingly, 5-HT levels were significantly elevated in patients with active CD but not active UC when compared with the levels in remission or refractory disease. Serum 5-HT was superior to C-reactive protein and circulating cytokines in differentiating between disease categories in CD. Additionally, SERT immunoreactivity was decreased in the ileum and colon of patients with CD compared to healthy controls. Conclusion We have shown that the serum 5-HT can differentiate between active disease and refractory disease or remission among CD patients, emphasizing the potential suitability of serum 5-HT as an auxiliary measure in diagnosing active CD.

show abstract

Section: Discussionmentioning

confidence: 99%

Serum Serotonin Differentiates Between Disease Activity States in Crohn’s Patients

Manzella

Jayawardena

Pagani

et al. 2020

Inflammatory Bowel Diseases

View full text Add to dashboard Cite

show abstract

“…We assume that no bias has been introduced due to the used (different) tests, since a good correlation between the QoC and other ELISA laboratory tests (Bühlmann Turbo) has been reported in the literature, as well as a similar accuracy for mucosal inflammation. 38 – 40 Thirdly, the sample size of our study is relatively small, and therefore subgroup analyses, including the separate analysis in UC and CD, might have been underpowered to detect differences. It is unlikely that the combined analysis of CD and UC has significantly influenced our results, since all patients with FC <250 µg/g at week 8 had endoscopic response at week 16; this value may serve as a cut-off to identify responders both in UC and in CD.…”

Section: Discussionmentioning

confidence: 97%

Fecal calprotectin is an early predictor of endoscopic response and histologic remission after the start of vedolizumab in inflammatory bowel disease

Pauwels

Woude

Erler

et al. 2020

Therap Adv Gastroenterol

View full text Add to dashboard Cite

Background and aims: Early prediction of the effect of vedolizumab (VDZ) in inflammatory bowel disease (IBD) is of paramount importance to guide clinical decisions. This study assessed whether early fecal calprotectin (FC) can predict endoscopic response and histologic remission after VDZ initiation. Methods: This was a prospective study. Inclusion criteria were endoscopic inflammation and FC >100 µg/g. FC was determined at baseline and weeks 2, 4, 8 and 16. At week 16, endoscopies with ileal and colonic biopsies were performed. FC changes were assessed with Wilcoxon Rank Sum tests. ROC statistics were used to assess the diagnostic accuracy of FC. Results: In total, 45 patients [27 Crohn’s disease (CD), 16/2 ulcerative colitis (UC)/IBD-unclassified] [40% males, median age 39 (28–51) years] were included. Week 16 endoscopic response and histologic remission rates were 58% and 33%. A median 37% decline in FC at week 2 was observed only in endoscopic responders, p = 0.025. FC <250 µg/g at week 8 predicted endoscopic response in both UC and CD (positive predictive value 100%), whereas absence of FC decline at week 8 corresponded with absence of endoscopic response in CD [negative predictive value (NPV) 82%] and absence of histologic remission in both UC and CD (NPV 90%). Conclusion: The onset of a decline in FC as early as week 2 is associated with endoscopic response to VDZ induction. FC <250 µg/g at week 8 is associated with endoscopic response, whereas absence of FC decline at week 8 is associated with absence of both endoscopic response and histologic remission. FC levels 8 weeks after the start of VDZ could be used to guide clinical decisions and might substitute for endoscopic response evaluation.

show abstract

“…The calprotectin concentrations in faeces (faecal calprotectin) provide one marker for inflammatory bowel diseases and are sensitive and easy to measure [ 31 ]. Elevated calprotectin levels have been described in both adults and children with inflammatory bowel diseases, such as Crohn’s disease and ulcerative colitis, and can be used to assess the severity of inflammation in these patients [ 32 ].…”

Section: Discussionmentioning

confidence: 99%

“…Elevated calprotectin levels have been described in both adults and children with inflammatory bowel diseases, such as Crohn’s disease and ulcerative colitis, and can be used to assess the severity of inflammation in these patients [ 32 ]. It has been found that faecal calprotectin levels can indicate cow’s milk allergy and atopic disease, as well as gastrointestinal disorders [ 2 , 20 , 30 , 31 ]. The diagnostic value of calprotectin in infancy is also of growing interest [ 33 , 34 ].…”

Section: Discussionmentioning

confidence: 99%

Lactobacillus rhamnosus GG (ATCC 53103) for the Management of Infantile Colic: A Randomized Controlled Trial

et al. 2020

View full text Add to dashboard Cite

Background: The aim of this study was to investigate the efficacy of Lactobacillus rhamnosus ATCC 53103 together with the maternal diet avoidance of cow’s milk in treating infantile colic. Methods: Forty-five colicky breastfed infants were consecutively randomized to receive L. rhamnosus for 28 days at a dosage of 5 × 109 cfu per day or placebo. Faecal samples were collected from each subject before starting supplementation and at the end of the study period and were immediately analysed. Faecal calprotectin was detected via a quantitative assay. The total bacterial load and selected bacterial species were evaluated using real-time TaqMan PCR. Results: After supplementation for 28 days with Lactobacillus rhamnosus ATCC 53103, median full-force daily crying was reduced (104 versus 242 min, p < 0.001) and the values of faecal calprotectin decreased significantly (p = 0.026). Furthermore, the probiotic increased the abundance of Lactobacillus (p = 0.048) and total bacteria (p = 0.040); all these effects were not observed in the placebo group. Conclusion: Infants treated with Lactobacillus rhamnosus ATCC 53103 for 28 days, in association with the elimination of cow’s milk from the maternal diet, presented some interesting features related to the effect of this probiotic treatment: reductions in crying time and faecal calprotectin, with increased total bacteria and Lactobacillus. To validate these results, a double-blind, placebo-controlled trial on a larger cohort is required.

show abstract

Clinical Accuracy of a New Rapid Assay for Fecal Calprotectin Measurement

Cited by 6 publications

References 0 publications

Serum Serotonin Differentiates Between Disease Activity States in Crohn’s Patients

Serum Serotonin Differentiates Between Disease Activity States in Crohn’s Patients

Fecal calprotectin is an early predictor of endoscopic response and histologic remission after the start of vedolizumab in inflammatory bowel disease

Lactobacillus rhamnosus GG (ATCC 53103) for the Management of Infantile Colic: A Randomized Controlled Trial

Contact Info

Product

Resources

About